Redirecting T cells to ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Lehner, Manfred ^a   Götz, Gabriel ^a   Proff, Julia ^a   Schaft, Niels ^a   Dörrie, Jan ^a   Full, Florian ^b   Ensser, Armin ^b   Muller, Yves A ^b   Cerwenka, Adelheid ^c   Abken, Hinrich ^d   Parolini, Ornella ^e   Ambros, Peter F ^f   Kovar, Heinrich ^f   Holter, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e Fondazione Poliambulanza Istituto Ospedaliero   (Italy)

^f CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD3ZETA ANTIGEN; CHIMERIC PROTEIN; FAS LIGAND; LENTIVIRUS VECTOR; LIGAND; LIPOCORTIN 5; MESSENGER RNA; MICA ANTIGEN; MICB ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ULBP 1 ANTIGEN; ULBP 2 ANTIGEN; ULBP 3 ANTIGEN; UNCLASSIFIED DRUG; HYBRID PROTEIN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADOPTIVE IMMUNOTHERAPY; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DOWN REGULATION; ELECTROPORATION; EWING SARCOMA; FLOW CYTOMETRY; GENE CONSTRUCT; GENE EXPRESSION; GENE FUSION; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; INTERMETHOD COMPARISON; INTERNALIZATION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROTEIN DOMAIN; STAINING; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; APOPTOSIS; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SARCOMA, EWING; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84857081656     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031210     Document Type: Article

References (51)

1. Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, et al. (2008) Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 51: 334-338.
2. Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, et al. (2007) Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Group. Pediatr Blood Cancer 49: 894-900.
3. Rodriguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, et al. (2007) Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 110: 375-384.
4. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, et al. (2008) NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 45: 3917-3925.
5. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, et al. (2010) Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16: 3901-3909.
6. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, et al. (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28: 955-959.
7. Kloess S, Huenecke S, Piechulek D, Esser R, Koch J, et al. (2010) IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol 40: 3255-3267.
8. Sadelain M, Brentjens R, Riviere I, (2009) The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 21: 215-223.
9. Nausch N, Cerwenka A, (2008) NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
10. Eagle RA, Traherne JA, Hair JR, Jafferji I, Trowsdale J, (2009) ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol 39: 3207-3216.
11. Zhang T, Lemoi BA, Sentman CL, (2005) Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551.
12. Zhang T, Barber A, Sentman CL, (2006) Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 66: 5927-5933.
13. Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, et al. (2007) Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 67: 5003-5008.
14. Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, et al. (2008) Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol 36: 1318-1328.
15. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121: 1822-1826.
16. McFarland BJ, Kortemme T, Yu SF, Baker D, Strong RK, (2003) Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure 11: 411-422.
17. Rosenberg SA, Dudley ME, (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240.
18. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, et al. (1993) Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8: 2683-2690.
19. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, et al. (1997) Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15: 2225-2232.
20. Van Valen F, (1998) Ewing's sarcoma family of tumors. In: Masters JRW, Palsson BO, editors. Human Cell Culture 1 Great Britain Kluwer pp. 55-85.
21. Textor S, Durst M, Jansen L, Accardi R, Tommasino M, et al. (2008) Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 123: 2343-2353.
22. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, et al. (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167: 6123-6131.
23. Full F, Lehner M, Thonn V, Goetz G, Scholz B, et al. (2010) T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol 84: 4083-4088.
24. Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, et al. (2009) Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther 16: 596-604.
25. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, et al. (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108: 4009-4017.
26. Lehner M, Morhart P, Stilper A, Petermann D, Weller P, et al. (2007) Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through Toll-like receptors. J Immunother 30: 312-322.
27. Saphire EO, Stanfield RL, Crispin MD, Parren PW, Rudd PM, et al. (2002) Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol 319: 9-18.
28. Barber DL, Wherry EJ, Ahmed R, (2003) Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 171: 27-31.
29. Salmon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, et al. (2000) High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96: 3392-3398.
30. Molinero LL, Fuertes MB, Rabinovich GA, Fainboim L, Zwirner NW, (2002) Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol 71: 791-797.
31. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, et al. (2010) Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol 184: 4284-4294.
32. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, et al. (2008) Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 180: 7028-7038.
33. Salih HR, Goehlsdorf D, Steinle A, (2006) Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67: 188-195.
34. Waldhauer I, Steinle A, (2006) Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 66: 2520-2526.
35. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, et al. (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20: 1819-1828.
36. Brinkrolf P, Landmeier S, Altvater B, Chen C, Pscherer S, et al. (2009) A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 125: 879-886.
37. Viola A, Lanzavecchia A, (1996) T cell activation determined by T cell receptor number and tunable thresholds. Science 273: 104-106.
38. Thomas S, Xue SA, Bangham C, Jakobsen BK, Morris E, et al. (2011) Human T cells expressing affinity matured TCR display accelerated responses but fail to recognise low density of MHC/peptide antigen. Blood doi:10.1182/blood-2010-12-326736.
39. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD, (2000) Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 74: 8207-8212.
40. Van Valen F, Fulda S, Truckenbrod B, Eckervogt V, Sonnemann J, et al. (2000) Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer 88: 252-259.
41. Sun Q, Burton RL, Lucas KG, (2002) Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood 99: 3302-3309.
42. de Hooge AS, Berghuis D, Santos SJ, Mooiman E, Romeo S, et al. (2007) Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res 13: 206-214.
43. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS, (2004) Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072.
44. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, et al. (1996) DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4: 573-581.
45. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, et al. (2009) NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 119: 1251-1263.
46. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M, (1998) Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 153: 1947-1956.
47. Sorkin A, Von Zastrow M, (2002) Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 3: 600-614.
48. Murphy JE, Padilla BE, Hasdemir B, Cottrell GS, Bunnett NW, (2009) Endosomes: a legitimate platform for the signaling train. Proc Natl Acad Sci U S A 106: 17615-17622.
49. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, et al. (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70: 9053-9061.
50. Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, et al. (2003) Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 170: 2161-2169.
51. Mitchell MS, Darrah D, Yeung D, Halpern S, Wallace A, et al. (2002) Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 20: 1075-1086.